could be ENMD's advantage........Aurora Kinase Inhibitors have Potential to be More Broadly Applicable than Other Targeted Cancer Therapies
Aurora kinase inhibition maybe a highly significant cancer therapeutic strategy for a number of reasons:
Aurora kinase activity is essential for the fundamental defect in cancer and the basis of its ability to cause harm, uncontrolled cell proliferation. If a cancer cell is prevented from proliferating, it cannot cause injury.
Aurora kinase inhibition, by stopping cell proliferation, also prevents a cancer cell from accruing additional mutations, the phenomenon that enables tumors eventually to escape the effects of anti-cancer drugs.
Inhibition of Aurora kinase activity freezes cancer cells in mitosis, which frequently pushes them into programmed cell death, or apoptosis. So Aurora kinase inhibition may kill cancer cells as well as merely stop their uncontrolled proliferation.
Aurora kinase activity is necessarily higher in proliferating cells than in resting cells (i.e., cells in the G1 phase of the cell cycle). This provides for some natural degree of selectivity, or targeting, of Aurora kinase inhibitors for cancer cells rather than normal, resting cells.
Because Aurora kinase acts in the last phases of the cell cycle, Aurora kinase inhibitors have the potential to be more broadly applicable and less likely to encounter resistance than other targeted cancer therapies 3,6,7,8,9,10 .
...........................................ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. Aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. ENMD-2076 exerts its effects through multiple mechanisms of action, including antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (e.g. breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells.
EN
AI
